GlassScriptPhysician profile
Maryana Liedke
NPI 1386987956
$114,656.56
in general payments reported to CMS, 2019-2025
71 companies · $36K in 2025
The $36K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,067 · 2020: $2,739 · 2021: $3,965 · 2022: $18K · 2023: $32K · 2024: $20K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Consulting Fee: $19K · Food and Beverage: $15K · Travel and Lodging: $6,913 · Education: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,047.50 |
| Consulting Fee | $19,466.50 |
| Food and Beverage | $15,180.25 |
| Travel and Lodging | $6,913.38 |
| Education | $319.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $50,479.71 | 2019-2025 | Vumerity, Tysabri, Tecfidera |
| Tg Therapeutics, INC. | $25,406.19 | 2023-2025 | |
| Emd Serono, INC. | $12,992.40 | 2019-2025 | Evobrutinib, Mavenclad, Mavenclad |
| Genentech USA, INC. | $6,940.59 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Abbvie INC. | $3,617.00 | 2021-2025 | |
| Amgen INC. | $1,373.54 | 2019-2025 | Uplizna, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,300.26 | 2019-2025 | |
| Genzyme Corporation | $1,059.64 | 2019-2025 | |
| Ucb, INC. | $734.81 | 2019-2023 | Briviact |
| Biohaven Pharmaceuticals, INC. | $720.12 | 2020-2021 | |
| Allergan, INC. | $702.07 | 2019-2022 | |
| Lundbeck LLC | $684.99 | 2019-2025 | Vyepti |
| Harmony Biosciences LLC | $672.94 | 2020-2025 | Wakix |
| Argenx US, INC. | $626.32 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Sk Life Science, INC. | $504.53 | 2020-2024 | Xcopri |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryana Liedke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.